GlobeNewswire: Applied Genetic Technologies Corporation Contains the last 10 of 272 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T15:17:10ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/12/01/2565756/0/en/Syncona-Limited-Portfolio-Company-Successfully-Completes-Tender-Offer-and-Acquisition-of-Applied-Genetic-Technologies-Corporation.html?f=22&fvtc=4&fvtv=21263Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation2022-12-01T12:00:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on November 30, 2022, and the acquisition was completed through a merger under Section 251(h) of the General Corporation Law of the State of Delaware. Pursuant to the terms of the definitive merger agreement, AGTC stockholders are entitled to receive $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.]]>https://www.globenewswire.com/news-release/2022/11/29/2563939/0/en/Syncona-Limited-Portfolio-Company-Extends-Tender-Offer-to-Acquire-Applied-Genetic-Technologies-Corporation.html?f=22&fvtc=4&fvtv=21263Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation2022-11-29T13:00:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights (CVRs) upon the achievement of specified milestones.]]>https://www.globenewswire.com/news-release/2022/11/28/2563160/0/en/FINAL-REMINDER-AGTC-Urges-Shareholders-to-Tender-Their-Shares-by-November-28-2022-FINAL-REMINDER.html?f=22&fvtc=4&fvtv=21263*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER*2022-11-28T13:30:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders:]]>https://www.globenewswire.com/news-release/2022/11/22/2561243/0/en/REMINDER-AGTC-Urges-Shareholders-to-Tender-Their-Shares-by-November-28-2022-REMINDER.html?f=22&fvtc=4&fvtv=21263*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*2022-11-22T21:05:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders:]]>https://www.globenewswire.com/news-release/2022/11/14/2555422/0/en/Applied-Genetic-Technologies-Corporation-Urges-Shareholders-to-Tender-Their-Shares-by-November-28-2022.html?f=22&fvtc=4&fvtv=21263Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 20222022-11-14T21:01:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the following letter to stockholders:]]>https://www.globenewswire.com/news-release/2022/11/03/2547668/0/en/Applied-Genetic-Technologies-Corporation-Reminds-Shareholders-to-Tender-Their-Shares-by-November-28-2022.html?f=22&fvtc=4&fvtv=21263Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 20222022-11-03T12:30:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, sent the following letter to shareholders:]]>https://www.globenewswire.com/news-release/2022/10/26/2542323/0/en/Syncona-Commences-Tender-Offer-for-All-Outstanding-Shares-of-Applied-Genetic-Technologies-Corporation.html?f=22&fvtc=4&fvtv=21263Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation2022-10-26T21:24:50Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass. and LONDON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC) (“AGTC” or the “Company”) and a newly established portfolio company of Syncona Limited (“Syncona”), a leading healthcare company focused on founding, building and funding global leaders in life science, announced the commencement today of the previously announced tender offer for all of the issued and outstanding shares of common stock of AGTC at a price of $0.34 per share in cash, at the closing of the transaction, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones (CVRs).]]>https://www.globenewswire.com/news-release/2022/10/24/2539624/0/en/Syncona-to-Acquire-Applied-Genetic-Technologies-Corporation.html?f=22&fvtc=4&fvtv=21263Syncona to Acquire Applied Genetic Technologies Corporation2022-10-24T02:05:21Z<![CDATA[Upfront consideration in cash of $0.34 per share representing a premium of approximately 42% over AGTC’s closing stock price on October 21, 2022]]>https://www.globenewswire.com/news-release/2022/09/01/2508488/0/en/AGTC-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=21263AGTC to Participate in Upcoming Investor Conferences2022-09-01T12:00:00Z<![CDATA[GAINESVILLE, Fla., and CAMBRIDGE, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:]]>https://www.globenewswire.com/news-release/2022/08/01/2489851/0/en/AGTC-to-Participate-in-Upcoming-Investor-Conferences.html?f=22&fvtc=4&fvtv=21263AGTC to Participate in Upcoming Investor Conferences2022-08-01T20:05:00Z<![CDATA[GAINESVILLE, Fla. and CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development and potential commercialization of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced that management will be participating in the following investor conferences:]]>